학술논문

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Document Type
Journal
Source
JOURNAL FOR IMMUNOTHERAPY OF CANCER; OCT 2022, 10 10, pe004235 13p.
Subject
Language
English
ISSN
20511426